Clinical Trials Logo
  1. Home
  2. Hodgkin Lymphoma
  3. NCT04396119
  4. Details
NCT04396119 Clinical Trial

Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study

Hodgkin Lymphoma Clinical Trial

Official title:
Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04396119
Other study ID # CFTSp178
Secondary ID 276443
Status Completed
Phase
First received
Last updated
Start date February 11, 2020
Est. completion date April 13, 2020

Study information
Verified date September 2020
Source The Christie NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To explore the topic of lung cancer screening following treatment for Hodgkin lymphoma from the perspective of survivors

Description:

Explore survivors' attitudes towards lung cancer and lung cancer screening Explore survivors' understanding of cancer screening as a concept and the benefits of screening and early detection Explore survivors' level of awareness of and attitudes towards their lung cancer risk Explore survivors' views on the barriers and motivating factors that would impact their decision to attend a lung cancer screening test

Recruitment information / eligibility
Status Completed
Enrollment 30
Est. completion date April 13, 2020
Est. primary completion date April 13, 2020
Accepts healthy volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Details held in the ADAPT database at The Christie NHS Foundation trust

- Responded to most recent ADAPT study questionnaire (April - August 2019)

- Aged 18-80

- Previously treated for Hodgkin lymphoma without evidence of relapse for at least 5 years

- Able to provide informed consent

- Treated with radiotherapy (with lung tissue in the radiotherapy field) and/or alkylating agent containing chemotherapy.

Exclusion Criteria:

- Previous or current diagnosis of lung cancer

- Stated within 2019 health questionnaire that they did not wish to be contacted

- Have participated in lung cancer screening through the Manchester Lung Health Checks

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
United Kingdom Christie NHS Foundation Trust Manchester

Sponsors (1)
Lead Sponsor Collaborator
The Christie NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome
Type Measure Description Time frame Safety issue
Primary Explore survivors' attitudes towards lung cancer and lung cancer screening Semi-structured interviews 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Active, not recruiting NCT03617666 - Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study Phase 2
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Recruiting NCT02507479 - Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies Phase 2
Active, not recruiting NCT02191930 - Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma Phase 2
Completed NCT01943682 - Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma Phase 1
Completed NCT01393106 - Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma Phase 2
Terminated NCT00992030 - R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma Phase 3
Terminated NCT00722865 - Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma Phase 2
Unknown status NCT00598624 - Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Phase 2
Completed NCT03242902 - To Decrease Fatigue With Light Therapy Phase 3
Active, not recruiting NCT05205512 - Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial N/A
Recruiting NCT03681561 - Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma Phase 1/Phase 2
Recruiting NCT03250962 - SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma Phase 2
Recruiting NCT04510610 - Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Phase 2/Phase 3
Completed NCT06295211 - Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.
Active, not recruiting NCT02256137 - A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer
Completed NCT02432235 - Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma Phase 1